Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth formulary coverage & PA update | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy US86

    2026 Formulary (List of Covered Drugs) — EmblemHealth Uniformed Sanitationmen's Association (US86)

    Customize your policy alerts

    Sign up for EmblemHealth Policy US86 alerts

    Get alerted when Policy US86 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the EmblemHealth formulary (US86) describing covered prescription drugs, tiers, utilization management (prior authorization, quantity limits, step therapy), and member services for the EmblemHealth Uniformed Sanitationmen's Association plan; it affects plan members, prescribing providers, and pharmacies.

    Policy Summary
    PayerEmblemHealth
    Policy2026 Formulary (List of Covered Drugs) — EmblemHealth Uniformed Sanitationmen's Association
    Policy CodePolicy US86
    Change TypeMinor editorial update — no material coverage changes
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization when a listed drug is designated PA, SP, or LA to avoid denial of coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-01-01effective date
    Tier 1–2drug tiers
    QL presentquantity limits
    PA, QL, ST, SP, LAUM abbreviations
    877-793-6253member services
    ~200drug entries (approx.)

    Formulary Coverage & Requirements

    Formulary coverage and utilization controls

    Covered when the formulary entry and any listed utilization controls are met:

    Formulary inclusion and tiering: Drugs listed are included on the EmblemHealth formulary with an assigned Drug Tier (e.g., Tier = 1 or Tier = 2) as shown next to each product.

    See product listing for specific tier assignment.

    Utilization controls applied to specific products: Some products include Requirements/Limits such as QL (quantity limits), SP (special program), or LA (limited access) which must be followed for coverage.

    Examples of QL, SP, and LA are shown in the product listings.

    Formulary product listing

    Each formulary product is listed with name, strength/form, Drug Tier, and any explicit Requirements/Limits (such as QL, SP, LA). Coverage follows the listed tiering and any Requirements/Limits.

    Policy Summary
    PayerEmblemHealth
    Policy2026 Formulary (List of Covered Drugs) — EmblemHealth Uniformed Sanitationmen's Association
    Policy CodePolicy US86
    Change TypeMinor editorial update — no material coverage changes
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization when a listed drug is designated PA, SP, or LA to avoid denial of coverage.
    SourceLink
    On This Page
    Formulary Coverage & RequirementsWhat Providers & Pharmacists Must DoQuantity Limits & Example CodesSelected Quantity Limits (Examples by Product)Specialty Distribution & Infusion RequirementsFormulary Terms & AbbreviationsStep Therapy — Presence and NotesPolicy Context & Scope
    Formulary entries: Each listed product includes drug name, strength/form, Drug Tier, and any explicit Requirements/Limits (such as QL or SP). Coverage follows the listed tiering and any Requirements/Limits.

    This document section is a product listing; clinical criteria are not provided in these entries.

    Not all products shown in this formulary are covered under every EmblemHealth drug benefit. The formulary itself does not guarantee payment — members and providers should confirm coverage, cost-sharing, and any plan-specific rules by consulting the member's Certificate of Coverage or calling the phone number on the member ID card prior to filling.

    Within the excerpted sections there are no explicit formulary exclusions listed; entries display drug name, strength, drug tier, and a Requirements/Limits field but do not specify excluded products in these chunks.

    Some listed items are noted as OTC in the Requirements/Limits field (for example, nonoxynol‑9 products such as ENCARE, OPTIONS GYNOL II, TODAY SPONGE). Products marked OTC may be available over the counter and their coverage as prescription benefits can differ from other formulary items.

    Several products in these sections are annotated as OTC or have blank Requirements/Limits fields; the presence of an OTC designation indicates over‑the‑counter status for those formulations and may affect coverage even though no formal exclusion language is provided in these chunks.

    In the provided document segments there are no statements labeling any drug as not medically necessary; the entries are product listings with Drug Tier and Requirements/Limits fields but do not include 'not medically necessary' language in these chunks.

    What Providers & Pharmacists Must Do

    Prior Authorization

    Obtain prior authorization when PA indicated

    Certain drugs require prior authorization (PA) before the plan will pay; if PA is not obtained coverage may be denied.

    Note

    Follow LA/SP designations (limited access or specialty)

    Some products include special requirement codes such as LA (Limited Availability) or SP (Specialty Drugs); these designations indicate additional utilization controls and may require special handling or authorization.

    Billing Rule

    Adhere to stated quantity limits (QL)

    Products annotated with explicit QL (Quantity Limit) must be dispensed within the listed limits; dispensing beyond the QL may not be covered.

    Prior Authorization

    Obtain PA / route through specialty for SP/LA antineoplastics

    Antineoplastic and other specialty agents marked SP or LA are subject to special program handling and likely require prior authorization or specialty pharmacy routing before coverage.

    Note

    Verify PA when not specified in formulary entry

    This segment lists drug tiers and Requirements/Limits fields but does not specify explicit prior authorization rules for every Tier 2 product; verify plan-specific PA requirements when not shown.

    Note

    Route SP/LA products through special programs

    Products marked SP or LA (specialty or limited access) indicate they are managed under special programs or limited distribution and may require additional authorization or specialty pharmacy processing.

    Prior Authorization

    PA required for listed LA/SP agents (examples)

    Examples of LA/SP agents (e.g., OFEV, ENTYVIO) are designated LA, SP in the formulary and therefore require prior authorization or enrollment in a special program prior to coverage.

    • OFEV — Requirements/Limits = LA, SP
    • ENTYVIO — Requirements/Limits = LA, SP
    Note

    Specialty handling required for SP/LA items

    Products with Requirements/Limits = SP or LA should be handled via specialty pharmacy or limited-access channels as indicated by the formulary.

    Prior Authorization

    Follow PA for DMTs flagged SP/LA

    Disease-modifying therapies and other specialty drugs annotated with SP or LA (for example dimethyl fumarate, fingolimod, cladribine, siponimod, diroximel fumarate) are subject to special program controls and prior authorization.

    • Tecfidera (dimethyl fumarate) — Requirements/Limits = SP/LA
    • Gilenya (fingolimod) — Requirements/Limits = SP/LA
    Prior Authorization

    Expect PA for biologic / LA-SP agents

    Biologic and specialty medications listed with Requirements/Limits = LA and/or SP (e.g., tocilizumab, apremilast, upadacitinib, tofacitinib) indicate prior authorization or specialty processing is likely required.

    • ACTEMRA (tocilizumab iv) — Requirements/Limits = LA, SP
    • RINVOQ (upadacitinib) — Requirements/Limits = LA, SP
    Note

    Confirm coverage when PA not listed

    Many formulary entries show Drug Tier and Requirements/Limits fields without explicit PA language; when prior authorization is not listed, confirm coverage by consulting plan resources or the member's Certificate of Coverage.

    Documentation Required

    Treat 'SP' as specialty processing flag

    Special processing indicator 'SP' appears adjacent to certain products (for example CIBINQO) and denotes specialty or special processing that may require specialty pharmacy workflows or authorization.

    Step Therapy

    Follow step therapy where indicated

    Some drugs are subject to step therapy (ST); the plan may require trying preferred agents first before covering alternatives.

    Note

    No ST sequence specified in formulary excerpt

    No explicit step therapy pathways or required trials are listed in this excerpt; do not assume a specific step sequence from these entries alone.

    Note

    Verify ST requirements when not listed

    This excerpt does not provide step therapy pathways for the listed products; verify any ST requirements via the plan's clinical prior authorization rules before prescribing.

    Note
    Step Therapy

    Route SP/LA products through step/authorization workflows

    Items marked SP or LA indicate they are subject to plan step/authorization processes and should be routed through the appropriate specialty or authorization channels.

    Note

    Absence of ST in excerpt — confirm with plan

    No step therapy sequences are listed in this excerpt; absence of ST notes does not mean step therapy is not required—confirm with plan authorization rules.

    Note

    Check plan for explicit step-therapy rules

    Step-therapy rules are not explicitly listed for many entries; individual SP/LA or tiering annotations may imply restrictions, but check plan-specific ST policies before treatment.

    Step Therapy

    Follow plan step-edit protocols when applicable

    Step therapy is not specified in this segment; follow plan protocols for any step edits that may apply.

    Note

    Verify ST applicability for each drug

    Step therapy requirements are not listed here; verify whether ST applies to the drug prior to prescribing or dispensing.

    Note
    Documentation Required

    Consult Certificate of Coverage for plan details

    Members should consult their Certificate of Coverage for plan-specific details on coverage, copays, and utilization requirements; the formulary alone does not guarantee payment.

    Billing Rule

    Dispense within listed QL examples

    Products annotated with QL must be dispensed within the listed quantity limits (examples include BIKTARVY QL 30 tablets/30 days and tafluprost PF QL 30 containers/30 days).

    • BIKTARVY — QL (30 tablets/30 days)
    • Tafluprost PF (Zioptan) — QL (30 containers/30 days)
    Billing Rule

    Ensure claim quantities match formulary QLs

    When submitting pharmacy claims, follow the product-specific QL shown on the formulary; claims exceeding listed QLs may be restricted or denied.

    Note
    Note
    Note
    Documentation Required

    Include required product details on claims

    Specify drug name, strength/form, and quantity on pharmacy claims consistent with the formulary entry and stated QL to avoid claim processing issues.

    Documentation Required

    Observe Tier and Requirements/Limits on claims

    Formulary entries include Drug Tier and Requirements/Limits fields; observe these fields when submitting pharmacy claims and when determining coverage pathways.

    Documentation Required

    Document quantity and duration to match QLs/OTC notes

    Document prescribed quantity and duration to align with QL or OTC designations where present; failure to do so may lead to denial or noncoverage.

    Documentation Required

    Provide specialty documentation for SP/LA drugs

    Many agents list Requirements/Limits = SP or LA (specialty or limited access), implying documentation or prior authorization through specialty pathways may be required.

    Documentation Required

    Confirm coverage for OTC-designated products

    OTC designations appear for some prenatal and vitamin products; OTC items may not be covered as prescriptions and should be confirmed against the Certificate of Coverage.

    Billing Rule

    Adhere to ophthalmic/topical QLs on claims

    Follow listed quantity limits for ophthalmic and topical products (for example tafluprost PF QL 30 containers/30 days; topical steroids with gram/ml QLs) when dispensing or submitting claims.

    • Tafluprost PF (Zioptan) — QL (30 containers/30 days)
    • Betamethasone dipropionate oint — QL (200 grams/28 days)
    Denial Risk

    Denial risk: no PA leads to noncoverage

    Failure to obtain prior authorization when required may result in the plan not covering the drug.

    Denial Risk

    Denial risk: exceeding QLs

    Claims exceeding listed quantity limits (QL) may be restricted or denied; examples include abacavir oral/solution limits and inhaler/blister limits per 30 days.

    • Abacavir solution — QL (960 mls/30 days)
    • Albuterol — QL (2 inhalers/30 days)
    Denial Risk

    Denial risk: exceeding product-specific QLs

    Claims may be denied if dispensing exceeds stated quantity limits such as QL (120 tablets/30 days) for certain products; check the specific QL for each drug.

    Denial Risk

    Denial risk: estradiol QLs may limit coverage

    Quantity limits are noted for certain estradiol products (for example Divigel and Climara), and exceeding those QLs may trigger coverage limitations or denial.

    • Divigel — QL (30 packets/30 days or 37.5 grams/30 days)
    • Climara — QL (4 patches/28 days)
    Denial Risk

    Denial risk: unspecified triggers require verification

    Some formulary entries list Drug Tier and 'Requirements/Limits =' placeholders without explicit denial triggers; absence of explicit denial language does not guarantee coverage—verify with the plan.

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Quantity Limits & Example Codes

    Quantity limits — inhaler / blister examples
    Albuterol inhalersQL 2 inhalers / 30 days
    Asmanex HFA and similar mometasone inhalersQL 1 inhaler / 30 days
    Advair Diskus and certain blister-pack inhalersQL 60 blisters / 30 days
    Quantity limits — Pulmicort Flexhaler and TRELEGY examples
    Pulmicort Flexhaler 90 mcgQL 1 inhaler / 30 days
    Pulmicort Flexhaler 180 mcgQL 2 inhalers / 30 days
    TRELEGY ELLIPTA (selected strengths)QL 60 blisters OR QL 1 inhaler / 30 days depending on strength/formulation as listed
    Tafluprost PF (Zioptan) quantity limit
    Tafluprost preservative-free (Zioptan)QL 30 containers / 30 days
    Drug TierTier = 1 (as listed)
    Route/Formophthalmic solution 0.0015%
    Travoprost quantity limit
    Travoprost (Travatan Z; benzalkonium-free)QL 2.5 mLs / 30 days
    Formulationophthalmic solution 0.004% (benzalkonium-free)
    Drug TierTier = 1 (as listed)
    Quantity limits — topical corticosteroid examples
    Clobetasol propionate topical formulationsQL 210 grams / 28 days (examples include cream/gel/foam)
    Betamethasone dipropionate augmented ointmentQL 200 grams / 28 days
    Betamethasone dipropionate cream/ointmentQL 135 grams / 30 days; lotion QL 120 mLs / 30 days
    Formulary abbreviations and definitions
    PA (Prior Authorization)Plan requires approval before filling; lack of PA may result in non-coverage
    QL (Quantity Limit)Maximum allowed supply for a drug over a defined time period (e.g., 1 inhaler/30 days)
    ST (Step Therapy)Plan may require trying specified drugs first before covering alternatives
    SP (Specialty)Specialty drugs that may require special handling, monitoring, or dispensing
    LA (Limited Availability)Drug may be available only at select pharmacies or via special distribution
    Drug tier examples
    Tier 1Preferred / lower-cost tier assignment example
    Tier 2Non-preferred / higher-cost tier assignment example
    UsageDrug Tier value is shown next to each product to indicate plan tiering

    Selected Quantity Limits (Examples by Product)

    Abacavir (Ziagen) quantity limit
    abacavir sulfate oral solution 20 mg/mL (Ziagen)QL 960 mLs / 30 days
    Formulationoral solution 20 mg/mL
    Drug TierTier = 1 (as listed)
    BIKTARVY quantity limit
    BIKTARVY (bictegravir/emtricitabine/tenofovir)QL 30 tablets / 30 days
    Formulationtablets (fixed-dose combination)
    Drug TierTier = 2 (as listed)
    COMPLERA quantity limit
    COMPLERA (emtricitabine-rilpivirine-tenofovir DF)QL 30 tablets / 30 days
    Formulationtablet fixed-dose combination
    Drug TierTier = 2 (as listed)
    Emtricitabine quantity limits
    Emtricitabine (Emtriva) — oral capsules/tabletsQL 30 capsules/tablets / 30 days
    Oral solution (Emtriva)QL 680 mLs / 28 days (where listed)
    Drug TierExamples include Tier = 1 or Tier = 2 depending on presentation
    Fosamprenavir quantity limit
    Fosamprenavir calcium tablets 700 mgQL 120 tablets / 30 days
    Drug TierTier = 1 (as listed)
    Indication contextAntiretroviral agent listed with QL in formulary
    LAGEVRIO (molnupiravir) quantity limit
    LAGEVRIO (molnupiravir) 200 mg capsulesQL 40 capsules / 30 days
    Drug TierTier = 2 (as listed)
    Formulationcapsules 200 mg
    GENVOYA quantity limit
    GENVOYA (elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide)QL 30 tablets / 30 days
    Drug TierTier = 2 (as listed)
    Formulationtablets (fixed-dose combination)
    INTELENCE quantity limit
    INTELENCE (etravirine) tabletsQL 60 tablets / 30 days
    Strengths noted100 mg, 200 mg formulations listed
    Drug TierTier = 1 or 2 depending on listing
    ISENTRESS quantity limits
    ISENTRESS (raltegravir) chewable/tablet formulationsQL up to 180 tablets / 30 days for certain chew/tab presentations
    Tablet 400 mgQL examples listed as 60 tablets / 30 days in other presentations
    Drug TierTier = 2 (as listed)
    Lamivudine oral solution quantity limit
    Lamivudine oral solution 10 mg/mL (Epivir)QL 960 mLs / 30 days
    Drug TierTier = 1 (as listed)
    Alternative solid formsTablets QL vary (e.g., 30–60 tablets/30 days)
    Lopinavir-ritonavir quantity limits
    Lopinavir-ritonavir (Kaletra) tablets 100/25 mgQL 180 tablets / 30 days (100/25 mg presentation)
    Alternate strength200/50 mg presentations show QL 120 tablets / 30 days
    Drug TierTier = 1 or 2 depending on listing
    PREZISTA oral suspension quantity limit
    PREZISTA (darunavir) oral suspension 100 mg/mLQL 400 mLs / 30 days
    PREZISTA tablets 600 mgQL 60 tablets / 30 days
    Other tablet strengthsOther tablet QLs noted (e.g., 30–300 tablets/30 days depending on strength)
    PREZISTA 600 mg tablet quantity limit
    PREZISTA tablets 600 mgQL 60 tablets / 30 days
    Drug TierTier = 2 (as listed)
    Formulation noteMultiple tablet strengths listed with differing QLs
    REYATAZ powder packet quantity limit
    REYATAZ oral powder packets 50 mgQL 240 packets / 30 days
    Drug TierTier = 2 (as listed)
    Formulationpowder packets for oral suspension
    STRIBILD quantity limit
    STRIBILD (elvitegravir-cobicistat-emtricitabine-tenofovir DF)QL 30 tablets / 30 days
    Drug TierTier = 2 (as listed)
    Formulationfixed-dose tablet
    Tenofovir disoproxil fumarate quantity limit
    Tenofovir disoproxil fumarate (Viread) 300 mg tabletsQL 30 tablets / 30 days
    Drug TierTier = 1 (as listed)
    Alternate strengthsMultiple strengths listed with QL 30 tablets/30 days in document
    Ritonavir (Norvir) quantity limit
    Ritonavir (Norvir) 100 mg tabletsQL 360 tablets / 30 days
    Drug TierTier = 1 (as listed)
    Formulation noteOral tablet presentations with high QL noted
    Zidovudine formulations quantity limits
    Zidovudine capsules 100 mg (Retrovir)QL 180 capsules / 30 days
    Zidovudine syrup 10 mg/mLQL 1920 mLs / 30 days
    Drug TierTier = 1 (as listed)
    Zidovudine syrup quantity limit
    Zidovudine oral syrup 10 mg/mLQL 1920 mLs / 30 days
    Capsule formQL 180 capsules / 30 days for 100 mg capsules
    Drug TierTier = 1 (as listed)
    Nevirapine suspension quantity limit
    Nevirapine suspension 50 mg/5 mLQL 1200 mLs / 30 days
    Nevirapine tablet QLsTablets show QLs such as 30–60 tablets/30 days depending on strength
    Drug TierExamples include Tier = 1–2 as listed
    Nitazoxanide quantity limit
    Nitazoxanide 500 mg tabletsQL 12 tablets / 90 days
    Drug TierTier = 1 (as listed)
    Coverage periodQL specified per 90-day period in listing
    CLIMARA PRO quantity limit
    CLIMARA PRO patchQL 4 patches / 28 days
    COMBIPATCHQL 8 patches / 28 days
    Climara estradiol patch exampleQL 4 patches / 28 days
    COMBIPATCH quantity limit
    COMBIPATCH (combination estradiol patch)QL 8 patches / 28 days
    Drug TierTier = 1 (as listed)
    Usage notePatch QLs listed per 28-day period in formulary
    Estradiol gel (Estrogel) quantity limit
    Estradiol gel (Estrogel)QL 1 pump / 30 days
    Formulationtopical gel preparation
    Drug TierTier = 1 (as listed)
    Divigel quantity limits
    Divigel topical gel packetsQL 30 packets / 30 days
    Divigel 1.25 mgQL 37.5 grams / 30 days (listed as 37.5)
    Drug TierTier = 1 (as listed)
    Divigel 1.25 mg quantity limit
    Divigel 1.25 mg (per packet) — numeric exampleQL 37.5 grams / 30 days (listed)
    Formulationestradiol topical gel strength example
    Coverage noteQL specified in formulary per 30 days
    Climara patch quantity limit
    Climara estradiol patch (weekly)QL 4 patches / 28 days
    Drug TierTier = 1 (as listed)
    Patch frequencyWeekly patch dosing; QL applies per 28 days
    Albuterol inhaler quantity limit
    Albuterol sulfate inhaler (e.g., Ventolin HFA)QL 2 inhalers / 30 days
    FormulationHFA inhaler 108 mcg/act (90 mcg base equiv)
    Drug TierTier = 2 for some inhaler listings
    Asmanex HFA and similar inhaler quantity limit
    Asmanex HFA and similar mometasone inhalersQL 1 inhaler / 30 days
    Formulations included100 mcg/act and other HFA/canister presentations
    Drug TierTier = 2 (as listed)
    Advair Diskus / blister inhaler quantity limit
    Advair Diskus and certain blister-pack inhalersQL 60 blisters / 30 days
    FormulationAdvair Diskus fluticasone-salmeterol aero powder
    Drug TierTier = 1 (as listed for Advair Diskus)
    Pulmicort Flexhaler quantity limit examples
    Pulmicort Flexhaler 90 mcgQL 1 inhaler / 30 days
    Pulmicort Flexhaler 180 mcgQL 2 inhalers / 30 days
    Combined notePulmicort Flexhaler QL varies by strength (1–2 inhalers/30 days)
    SPIRIVA HandiHaler quantity limit
    SPIRIVA HandiHaler capsules (tiotropium)QL 30 capsules / 30 days
    FormulationHandiHaler inhalation capsules 18 mcg
    Drug TierTier = 2 (as listed)
    Pulmicort Flexhaler 90 mcg quantity limit
    PULMICORT FLEXHALER 90 mcgQL 1 inhaler / 30 days
    Drug TierTier = 2 (as listed)
    FormulationBudesonide inhalation powder, breath-activated
    Pulmicort Flexhaler 180 mcg quantity limit
    PULMICORT FLEXHALER 180 mcgQL 2 inhalers / 30 days
    Drug TierTier = 2 (as listed)
    Formulation noteHigher strength allows 2 inhalers per 30 days as listed
    QVAR REDIHALER quantity limits
    QVAR REDIHALER 40 mcgQL 1 inhaler / 30 days
    QVAR REDIHALER 80 mcgQL 2 inhalers / 30 days
    Drug TierTier = 2 (as listed)
    SEREVENT / TRELEGY / SPIRIVA examples
    SEREVENT DISKUS (salmeterol)QL 60 blisters / 30 days
    TRELEGY ELLIPTAQL varies by strength; examples include 60 blisters or 1 inhaler / 30 days
    SPIRIVA HANDIHALERQL 30 capsules / 30 days
    SPIRIVA HandiHaler / Respimat quantity limits
    SPIRIVA HandiHalerQL 30 capsules / 30 days
    SPIRIVA RespimatQL 1 inhaler / 30 days (Respimat presentation)
    Drug TierTier = 2 for HandiHaler listings
    TRELEGY ELLIPTA quantity limit (example)
    TRELEGY ELLIPTA 200-62.5-25 mcg/actQL 1 inhaler / 30 days (example listing)
    Alternate TRELEGY strengthsOther strengths may show different QLs (see listing)
    Drug TierTier = 2 (as listed)
    VENTOLIN HFA quantity limit
    VENTOLIN HFA (albuterol HFA)QL 2 inhalers / 30 days
    FormulationHFA inhaler 108 mcg/act (90 mcg base equiv)
    Drug TierTier = 2 (as listed)
    Solifenacin (Vesicare) quantity limit
    Solifenacin succinate (Vesicare) 5 mg, 10 mgQL 30 tablets / 30 days
    Drug TierTier = 1 (as listed)
    FormulationOral tablets
    Tolterodine examples (duplicate reference)
    Tolterodine 1 mgQL 60 tablets / 30 days
    Tolterodine ER capsQL 30 capsules / 30 days
    Drug TierTier = 1 (as listed)
    Tolterodine 1 mg quantity limit
    Tolterodine 1 mg tabletsQL 60 tablets / 30 days
    Drug TierTier = 1 (as listed)
    Alternate presentationsER caps show QL 30 capsules / 30 days
    Estradiol vaginal cream quantity limit
    Estradiol vaginal cream (Estrace) 0.01%QL 255 grams / 365 days
    Formulationvaginal cream presentation
    Drug TierTier = 1 (as listed)
    ESTRING quantity limit
    ESTRING (estradiol vaginal ring)QL 1 ring / 90 days
    Formulationvaginal ring 2 mg (7.5 mcg/24 hr)
    Drug TierTier = 2 (as listed)
    Evekeo quantity limit
    Amphetamine sulfate (Evekeo) 5 mg tabletsQL 90 tablets / 30 days
    Alternate Evekeo strength10 mg listing shows QL 180 tablets / 30 days
    Drug TierTier = 1 (as listed)
    Adderall XR quantity limit
    Adderall XR (amphetamine-dextroamphetamine) ER capsulesQL 30 capsules / 30 days
    Drug TierTier = 1 (as listed)
    Formulation noteExtended-release capsule presentations specified
    Adderall tablets quantity limits
    Adderall immediate-release tabletsQL 60 tablets / 30 days
    Adderall 20 mgQL 90 tablets / 30 days for certain strengths
    Drug TierTier = 1 (as listed)
    Adderall 20 mg quantity limit
    Adderall 20 mg tablets (example)QL 90 tablets / 30 days
    Drug TierTier = 1 (as listed)
    UsageHigher QL for specific strengths noted in formulary
    Mydayis quantity limit
    Mydayis ER 3-bead cap ERQL 30 capsules / 30 days
    Formulation3-bead extended-release capsule
    Drug TierTier = 1 (as listed)
    Atomoxetine quantity limit
    Atomoxetine capsules (various strengths)QL 60 capsules / 30 days (common example)
    Alternate QLsSome atomoxetine strengths list QL 30 capsules / 30 days
    Drug TierTier = 1 (as listed)
    CIBINQO (abrocitinib) designation
    CIBINQO (abrocitinib) tablets 50/100/200 mgRequirements/Limits = SP (special program) — specialty processing designation
    Drug TierTier = 2 (as listed)
    ImplicationSP label indicates special program handling or prior authorization may apply
    Topical steroid quantity limit examples (detailed)
    Clobetasol propionate topical formsQL 210 grams / 28 days (multiple formulations)
    Fluocinolone acetonide creamQL 120 grams / 30 days
    Desonide / desoximetasone examplesQL 120 grams / 30 days

    Specialty Distribution & Infusion Requirements

    Note

    Route antineoplastics to infusion center or specialty pharmacy

    Some antineoplastic and specialty agents flagged SP/LA likely require specialty pharmacy distribution or administration in an infusion/site program rather than standard retail dispensing.

    Note

    Infusion center routing for LA/SP IV biologics

    IV biologics and infusion products listed with SP or LA designations are managed in the infusion/site program and should be routed accordingly.

    Note

    Use specialty pharmacy for SP/LA medications

    Agents marked SP or LA are likely to require specialty pharmacy handling or limited-access distribution channels; coordinate with specialty pharmacies for authorization and dispensing.

    Formulary Terms & Abbreviations

    Step Therapy — Presence and Notes

    Product / ExampleDesignationImplication for Step Therapy / Access
    TOBI PODHALER (tobramycin inhal cap 28 mg)LA, SPLA/SP flags indicate limited access or specialty program placement; access controlled per plan rather than explicit step edits in the listing
    Deflazacort (Emflaza) formulationsLA, SPLA/SP designation implies special access handling; follow plan-specific authorization or specialty processes instead of a stated step sequence
    RINVOQ (upadacitinib) and oral solutionLA, SPLA/SP indicates specialty or limited access — may require prior authorization or specialty routing; no explicit step therapy sequence provided
    Step Sequence NameDescription / Drugs IncludedPresence in Document
    N/A — no step sequences providedNo explicit step therapy pathways or required trials are listed in the provided excerptNo
    Product / ClassLA or SP FlagPlan Action (authorization / routing)
    Bosentan (Tracleer)SPMarked SP — specialty program placement; follow plan prior authorization and specialty pharmacy processes
    NUPLAZID (pimavanserin)LA, SPDesignated LA/SP — limited access and specialty handling; plan-specified prior authorization/specialty workflows apply
    OTEZLA (apremilast)SPSP indicates specialty processing; follow plan authorization requirements and specialty dispensing routes
    Tier / Product groupQuantity Limits (example)Step Therapy Sequence Present?
    Respiratory inhalers (PULMICORT FLEXHALER, QVAR, TRELEGY)Examples: PULMICORT 90 mcg = QL 1 inhaler/30 days; PULMICORT 180 mcg = QL 2 inhalers/30 days; TRELEGY = QL 1 inhaler/30 daysNo — only tiers and QLs provided; no step therapy steps listed
    Blister-pack inhalers (SEREVENT DISKUS)QL 60 blisters/30 daysNo
    DesignationMeaning in DocumentExample Entries
    SP (Special Program / Specialty)Indicates specialty program handling or special processing; may require specialty pharmacy or prior authorizationExamples: TOBI nebulized solutions = SP; BOSENTAN = SP
    LA (Limited Access)Indicates limited access — product access restricted and likely requires additional authorization or routingExamples: TOBI PODHALER = LA, SP; NUPLAZID = LA, SP; RINVOQ = LA, SP
    Therapeutic Area / Example DrugsSP/LA NotationPotential Effect (step edits / additional controls)
    Immunomodulators / JAK inhibitors (apremilast, upadacitinib, tofacitinib)OTEZLA = SP; RINVOQ = LA, SP; XELJANZ = SPSP/LA designations indicate specialty processing and likely prior authorization or routing; may be subject to plan step edits though no sequences are listed in excerpt
    Corticosteroids / Selected specialty agents (deflazacort)LA, SPLA/SP flags denote limited access or specialty program placement — follow plan authorization workflows

    Policy Context & Scope

    This document is the EmblemHealth drug formulary listing covered medications by name, strength/form, assigned Drug Tier, and any stated Requirements/Limits (examples include QL, SP, LA, or OTC). The listing identifies drugs subject to utilization controls (e.g., quantity limits or specialty/limited‑access designations) and serves as reference for prescribing, dispensing, and benefit determination.